Ultragenyx Pharmaceutical Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of RARE for the last quarter is 108.83 M USD, and it's 14.57% lower compared to the previous quarter. The net income of Q1 24 is -170.68 M USD.